INLUENCE OF OSTEOPOROSIS AND ITS CAUSATIVE FACTORS ON THE PREVENTION OF RECURRENCE OF URINARY STONE DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. The aim of postoperative examination, treatment and follow-up of patients with urinary stone disease is a prevention of recurrence. A choice of method of prevention is based on the results of postoperative examination with consideration of etiological factors of urinary stone disease. An analysis of influence of osteoporosis and its causative factors on the recurrence of urinary stone disease is presented in the article. Aim: to clarify the influence of osteoporosis and its causative factors on excretion of calcium, uric acid and recurrence of urinary stone disease. Materials and methods. A total of 86 patients after surgical treatment of urinary stone disease were included in the study. A physicochemical analysis of stones and their fragments, excretion of calcium and uric acid were done postoperatively. The risk factors for osteoporosis were identified using specific questionnaire. Bone mineral density (BMD) was assessed by X-ray densitometry. After X-ray phasic analysis of the stones and studying of the daily excretion of calcium and uric acid, 10 and 7 patients were prescribed to thiazide diuretics and allopurinol, respectively. In 69 patients (80.2%) there were no indications to the treatment and all of them were included in control surveillance group. Results. Calcium oxalate stones were predominated in patients who were under surveillance (p=0,0254). A prevalence of risk factors for osteoporosis was similar in all groups (р=0,2156), as well as rate of decrease in BMD (р=0,64). In patients taking thiazide diuretics, a significant decrease in daily calcium excretion was found (р=0,0054) without significant changes in excretion of uric acid and diuresis volume. Among patients receiving allopurinol there was a significant decrease in daily uric acid excretion (р=0,021), without significant changes in excretion of calcium and diuresis volume. There were no significant changes of these values in the control group. A recurrence of urinary stone disease in treatment group was detected in 4 patients with a decrease of BMD after 381±61 days, while in control group there were 5 recurrences in patients with decreased BMD and I recurrence in patient with normal BMD after 836±64 days. Conclusion. Treatment aimed at prevention of recurrence of urinary stone disease allows to correct detected metabolic disturbances. However, such factor as the decrease in BMD can influence on the rate and frequency of recurrence of urinary stone disease. A clarifying of risk factors for osteoporosis and diagnosis of osteoporosis allow to give reliable recommendations for its treatment and to decrease risk of recurrence of urinary stone disease.

Full Text

Restricted Access

About the authors

L. S Demidko

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: klubnika47@yandex.ru
Ph.D. student, Institute for Urology and Human Reproductive Health Moscow, Russia

V. I Rudenko

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: rudenko-vadim@rambler.ru
MD, professor Moscow, Russia

V. V Fadeev

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: thyroclin@gmail.com
corresponding member of RAS, professor, MD, Head of the Department of Endocrinology Moscow, Russia

Yu. L Demidko

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: demidko1@mail.ru
MD, physician at the Institute for Urology and Human Reproductive Health Moscow, Russia

A. V Amosov

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: amosov-av@yandex.ru
MD, professor at the Institute for Urology and Human Reproductive Health Moscow, Russia

G. M Kuz’micheva

Physicotechnological institute “MIREA-Russian technological university”

Email: galina_kuzmicheva@list.ru
Doctor of Chemical Science, professor, Department of Physics and Chemistry of Materials named after B.A. Dogadkin Moscow, Russia

V. A Grigoryan

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: doctor-grigoryan@mail.ru
MD, professor at the Institute for Urology and Human Reproductive Health Moscow, Russia

M. E Enikeev

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: enikmic@mail.ru
MD, professor at the Institute for Urology and Human Reproductive Health Moscow, Russia

M. V Amosova

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: amosov-av@yandex.ru
Ph.D. student at the Department of Endocrinology Moscow, Russia

References

  1. Rudenko V.I.,SemenyakinI.V.,Malhasyan V.A., Gadjiev N.K. Russian clinical guidelines. Urinary stone disease. Urology. 2017;2(Supplement):30-63.
  2. Türk C., Neisius A., Petrik A., Seitz C., Skolarikos A., Tepeler A., Thomas K. EAU Guidelines. 2017.
  3. Arrabal-Marti'n M., Cano-Garci'a M.C., Arrabal-Polo M.Á., Domínguez-Amillo A., Canales-Casco N., de la Torre-Trillo J., Cózar-Olmo J.M. Etiopathogenic factors of the different types of urinary litiasis. Arch Esp Urol. 2017;70(1):40-50.
  4. TaylorE.N., Feskanich D., Paik J.M., Curhan G.C. Nephrolithiasis and Risk of Incident Bone Fracture. J Urol. 2016;195(5):1482-1486.
  5. Yasui T., Okada A., Hamamoto S., Ando R., Taguchi K., Tozawa K., Kohri K. Pathophysiology-based treatment of urolithiasis. Int J Urol. 2017;24(1)32-38.
  6. Kozyrakis D., Paridis D., Karatzas A., Soukias G., Dailiana Z. Do Calcium Supplements Predispose to Urolithiasis? Curr Urol Rep. 2017;18(3):17.
  7. Leslie S.W., TanejaA. Hypercalciuria. StatPearls Publishing, 2018.
  8. Glezer M.G. Diuretics. M.: Interbuk, 1993. Russian (Глезер М.Г. Диуретики. М.: Интербук, 1993).
  9. Isakova T., Anderson C.A., LeonardM.B., XieD., Gutiérrez O.M., Rosen L.K., Theurer J., Bellovich K., Steigerwalt S.P., TangI.,Anderson A.H., Townsend R.R, He J., Feldman H.I., Wolf M. Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant. 2011;26(4):1258-1265.
  10. Ceylan K., Topal C., Erkoc R., Sayarlioglu H., Can S., Yilmaz Y., Dogan E., Algun E., Gonulalan H. Effect of indapamide on urinary calcium excretion in patients with and without urinary stone disease. Ann Pharmacother. 2005;39(6):1034-1038.
  11. Favus M.J., Coe F.L. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Scand J Urol Nephrol Suppl. 1980;53:265-271.
  12. US National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. 2010.
  13. WHO Scientific Group on the Prevention and Management of Osteoporosis. report of a WHO scientific group (WHO Technical Report series;921). Geneva. 2000.
  14. Benevolenskaya L.I., Lesnyak O.M. Osteoporosis. Diagnosis, prevention and treatment. M.: GEOTAR-Media 2005.
  15. MedCalc Statistical Software version 17.0.4: (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2017), 2017.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies